|
|
|
Issue Open Date
|
10-Aug-26
|
|
|
|
Issue Closing Date
|
12-Aug-26
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
768
-
807
|
|
|
|
Minimium Application No.
|
18
|
|
|
|
Issue Size (Shares)
|
11772311
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
|
Objective
|
|
1. Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space,2. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and3. General corporate purposes
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
|
|
|
|
Qualified Institutional Buyers
|
|
|
|
|
Retail Individual Investors
|
|
|
|
|
|
|
|
Business Description:
We are an innovative point-of-care (“POC”) diagnostics company focused on expanding access to accurate, rapidand cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. We havedeveloped our ‘Truenat’ platform, which is a novel POC polymerase chain reaction (“PCR”) platform that canoperate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.As of March 31, 2025, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious andnon-communicable diseases. As of March 31, 2025, we offer molecular testing for 30 diseases, includingtuberculosis (“TB”), COVID, Hepatitis B and C, Human immunodeficiency virus (“HIV”), and HumanPapillomavirus (“HPV”) with 42 assays. We operate in an oligopolistic market with high entry barriers, evidencedby the fact that our platform underwent 13 years of R&D to obtain Indian Council of Medical Research (“ICMR”)certification and our ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of theonly two rapid molecular tests in the world, which has been endorsed by the World Health Organization (“WHO”)for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. (Source:1Lattice Report). We also provide devices, enabling radiology, digital pathology and breast health screening,through our Subsidiary, Prognosys, Associate, OptraScan and collaboration partner - UE Lifesciences. Further, weare focussed towards building a pipeline of additional products and platforms that are currently at various stagesof development.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
52597450
|
|
|
|
Offered to Public
|
11646246
|
|
|
|
Promoter's Holding (Pre-Issue)
|
46.65
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
|
Address |
Plot No. L-46
Phase I I- D
Verna Industrial Area
Verna
Salcete
South Goa
,
Goa
,
403722
Phone :
0832 6724888
Email :
investors@molbiodiagnostics.com
Website :
www.molbiodiagnostics.com
|
|
|
|
Registrar |
KFIN Technologies Ltd.
301
The Centrium
3rd Floor
57
Lal Bahadur Shastri Road
Nav Pada
Kurla (West)
Mumbai
|
|
|
|
Listed at |
|
BSE, NSE
|
|
|
|
Lead Manager |
IIFL Capital Services Ltd.
Jefferies India Pvt Ltd.
Kotak Mahindra Capital Co Ltd
Motilal Oswal Investment Advisors Pvt Ltd
|
|
|
|
Promoters |
Chandrasekhar Bhaskaran Nair
Exxora Trading LLP
Sangeetha Sriram
Sowmya Sriram
Sriram Natarajan
|
|
